Welcome, Guest. Please login or register.
June 15, 2024, 04:24:44 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55127
  • Total Topics: 4851
  • Online Today: 117
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 79
Total: 79


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: AbbVie’s Mavyret Cures Hep C at High Rates in Real-World Analysis  (Read 4436 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
A real-world analysis of AbbVie’s Mavyret (glecaprevir/pibrentasvir) found the hepatitis C virus (HCV) treatment was highly effective and well tolerated, MedPage Today reports.

Researchers conducted a retrospective longitudinal study of people with hep C starting Mavyret at 30 clinics in Italy. The study looked at the traditional indicator of whether someone has been cured of hep C, a sustained virologic response 12 weeks after completing therapy (SVR12), and also determined the proportion of those who had achieved an SVR four weeks after completing therapy (SVR4). Someone with an SVR4 stands an excellent chance of maintaining an undetectable hep C viral load for another eight weeks and then achieving an SVR12.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.